Background: Overweight and hepatic steatosis have been increasingly recognized recently. This study aimed to test whether substantial amount of fatty infiltration in liver, which may interfere with cytoplasmic distribution of hepatitis B surface antigen (HBsAg), can contribute to HBsAg seroclearance in HBsAg carriers. Methods: Clinical and laboratory data including ultrasound grading of hepatic steatosis were studied in 54 HBsAg carriers with HBsAg seroclearance, and the results were compared with 108 age-and sex-matched carriers with HBsAg persistence. Results: Body mass index and ultrasound grading of hepatic steatosis were significantly higher in HBsAg carriers with HBsAg seroclearance than in those with HBsAg persistence. The degrees of hepatic steatosis correlated significantly with body mass index (Po0.001). The prevalence of mild hepatic steatosis showed no significant difference (33% (18/54) vs 31% (33/108), P ¼ 0.72), but moderate-severe hepatic steatosis was significantly more prevalent in patients with HBsAg seroclearance (33% (18/54) vs 13% (17/108), P ¼ 0.01). HBsAg carriers with moderate and severe hepatic steatosis were associated with a 3.2-fold (95% confidence interval: 1.2-8.4, P ¼ 0.02) and 3.9-fold (95% confidence interval: 1.1-14.2, P ¼ 0.04), respectively, increased odds of HBsAg seroclearance compared to those without hepatic steatosis. Conclusion: Moderate-severe hepatic steatosis may contribute to HBsAg seroclearance in HBsAg carriers.
Introduction
The natural history of chronic hepatitis B virus (HBV) infection consists of three phases:
1,2 an initial immune tolerant phase (hepatitis B e antigen (HBeAg) positive and normal alanine aminotransferase (ALT) levels), followed by immune clearance phase (HBeAg and abnormal ALT levels), and finally the low replication phase (hepatitis B e antibody (anti-HBe) positive and normal ALT levels). Patients in the third phase are usually termed 'inactive carriers' -they are positive for hepatitis B surface antigen (HBsAg) but negative for HBeAg, have normal ALT levels and low serum levels HBV DNA (o10 5 genome copies/ml).
Serum HBsAg may become negative with time in inactive carriers. The annular incidence of HBsAg seroclearance is estimated to be 0.5-2.0%. [3] [4] [5] [6] [7] [8] Several factors have been identified to be significantly associated with HBsAg seroclearance in chronic HBV infection, such as age 440 years, presence of liver cirrhosis, hepatitis C or D virus superinfection. 4, 9, 10 However, a high percentage of HBsAg carriers with HBsAg seroclearance did not have identified causes. For example, in one series reported from Taiwan, only 20% of patients had hepatitis C or D virus superinfection and 13% had evidence of liver cirrhosis, whereas the other 67% did not have attributable causes. 11 The causes of HBsAg seroclearance in chronic HBV infection thus remain largely unknown. Obesity and hepatic steatosis are increasingly recognized worldwide. Many HBsAg carriers are found to have ultrasound evidence of hepatic steatosis during screening for hepatocellular carcinoma. Hepatic steatosis associated with overweight or obesity is usually macrovesicular type; hepatocytes are enlarged and the cytoplasm is filled with one or more large fat droplets that displace the nucleus to eccentric position. Immunohistochemical studies revealed that there is a widespread expression of HBsAg in the hepatocyte cytoplasm in inactive carriers 12, 13 and HBsAg became undetectable in hepatocyte after HBsAg seroclearance. 4 One interesting issue raised is whether substantial amount of fatty infiltration in liver, which may interfere with cytoplasmic distribution of HBsAg, can contribute to HBsAg seroclearnace in chronic HBV infection. In this study, the clinical and laboratory data including body mass index and ultrasound grading of hepatic steatosis were compared between 54 HBsAg carriers with HBsAg seroclearance and 54 age-and sex-matched controls with HBsAg persistence.
Materials and methods

Patients
Asymptomatic HBsAg carriers who were positive for anti-HBe and had normal or minimally elevated ALT (o1.5 times the upper normal limit) were followed up periodically every 6 months at the carrier clinic of Chang Gung Memorial Hospital, Taipei, Taiwan, as reported previously. 14 16 were excluded. A double number of age-and sex-matched HBsAg carriers with HBsAg persistence were randomly selected as controls. As body weight and degrees of hepatic steatosis might vary with time, only patients who had change in body weight o10% or degrees of hepatic steatosisp one score in the last 3 years were included for study.
Laboratory methods
HBsAg, antibody against HBsAg (anti-HBs), HBeAg, anti-HBe and antibody against hepatitis D virus were assayed using commercially available radioimmunoassay kits (Ausria-II, HBeAg-RIA and anti-delta, Abbott Laboratories, North Chicago, IL, USA). Antibodies against hepatitis C virus were tested by a commercially available third-generation enzyme immunoassay kit (HCV EIA III; Abbott Laboratories). Routine ultrasound was performed as a part of surveillance of hepatocellular carcinoma with a high-resolution, realtime scanner (Aloka SSD-1200, -630, -650; Tokyo, Japan) using a 3.5-and 5.0-MHz rectilinear or convex transducer. All examinations were carried out by ultrasound specialists. Hepatic steatosis was graded as mild-to-moderate or severe according to the hepatic echogenicity: the features of mildto-moderate liver steatosis were a slight increase in liver echogenicity with a slight exaggeration of liver and kidney echo discrepancy (mild) or loss of echoes from the wall of the portal vein with a greater posterior beam attenuation and greater discrepancy between hepatic and renal echoes (moderate); the features of severe steatosis were a greater reduction in beam penetration, loss of echoes from most of the portal vein wall and an even larger discrepancy between hepatic and renal echoes. [17] [18] [19] [20] 
Statistical analysis
Results
Fifty-four HBsAg carriers with HBsAg seroclearance and 108 age-and sex-matched HBsAg carriers with HBsAg persistence were studied. These carriers were identified incidentally during blood donation or health test. None of them had previous history of acute hepatitis, so the time point of infection was unknown. All patients did not admit intravenous drug abuse or homosexual activities. The clinical and laboratory data of the study patients are listed in Table 1 . Thirty-two (59%) of HBsAg carriers became positive for antiHBs after HBsAg seroclearance. HBsAg carriers with HBsAg seroclearance had significantly higher ultrasound grading of hepatic steatosis than those with HBsAg persistence (Table 1 ). The prevalence of mild 
Discussion
The impact of hepatic steatosis on the natural course of chronic HBV infection has been much less recognized, 22 as in chronic hepatitis C virus infection. 23, 24 The aim of the present study is to correlate hepatic steatosis with HBsAg seroclearance in inactive HBsAg carriers. In this study, hepatic steatosis was graded by ultrasound, which was shown to have a sensitivity of 89-94% and a specificity of 84-93% in detecting steatosis, 18, 20 and the sensitivity and specificity can be high up to 100% in detecting moderate or severe steatosis. 17 Our data revealed that HBsAg carriers with HBsAg seroclearance had significantly higher body mass index and ultrasound grading of hepatic steatosis than HBsAg carriers with HBsAg persistence (Tables 1 and 2 and Figure 1 ). The degrees of hepatic steatosis correlated highly significantly with body mass index in HBsAg carriers with HBsAg seroclearance or in those with HBsAg persistence, suggesting that overweight or obesity is the major factor for hepatic steatosis in chronic HBV infection, as reported previously. 22 The prevalence of type II diabetes mellitus showed no significant difference, and other common causes of hepatic steatosis, such as alcoholic, drug-related or nutritional, were excluded in both groups of patients. Unfortunately, data on hyperlipidemia were incomplete and not included in this study. Perhaps, one limitation of this study is that data on HBV genotypes were not available owing to inadequate serum samples. The most prevalent HBV genotypes in Southeast Asia and Taiwan are genotypes B and C, 25 and a recent study from Hong Kong showed that patients with genotype B had a higher chance of spontaneous HBsAg seroclearance than those with genotype C. 26 Whether the difference in body mass index and ultrasound grading of hepatic steatosis between patients with HBsAg seroclearance and those with HBsAg persistence remains significant after correction of the HBV genotype is unknown. HBsAg carriers with mild hepatic steatosis did not have increased likelihood of HBsAg seroclearance, but moderatesevere hepatic steatosis was associated with three-to fourfold increased odds of HBsAg seroclearance compared to those with no evidence of hepatic steatosis (Table 2) . These data may be compatible with our suggestion that substantial amount of fatty infiltration in the liver may contribute to HBsAg seroclearance. Unfortunately, no liver histology was available from these inactive carriers, because all were asymptomatic and had normal or minimally elevated ALT. Further studies are indicated to see the relationship between the extent of cytoplasmic distribution of HBsAg and the degree of hepatic steatosis in inactive HBsAg carriers with low levels of viral replication and histological activity. HBsAg clearance HBsAg persistence Hepatic steatosis and HBsAg seroclearance C-M Chu et al Alternatively, HBsAg seroclearance in patients with hepatic steatosis also may be due to steatosis-induced apoptosis and inflammation. Cytotoxic T cells specific for HBsAg are present in the peripheral blood of patients with chronic HBV infection, but they are quantitatively insufficient to mediate viral clearance. 27 Notably, Fas receptor is strongly expressed in hepatocytes from patients with nonalcoholic steatohepatitis. 28 It may be likely that the enhanced expression of Fas receptor by hepatocytes chronically infected with HBV can lead to increased susceptibility of these cells to apoptosis and facilitate clearance of the virus. Interestingly, one recent population-based study from Taiwan revealed that there was an inverse relationship between metabolic syndrome and chronic HBV but not hepatitis C virus infection: the likelihood of developing metabolic syndrome was significantly lower in HBsAgpositive subjects than in HBsAg-negative subjects after controlling other confounding factors. 29 The reason why HBsAg-positive subjects are less prone to have metabolic syndrome remains unclear. One possible explanation may be related to the present findings: as HBsAg carriers who had higher body mass index with higher ultrasound grading of hepatic steatosis tend to clear HBsAg from serum, the HBsAgpositive subjects enrolled in the population-based study are likely those who have relatively lower body mass index and thus lower prevalence of metabolic syndrome. Finally, it should be pointed out that, although moderatesevere hepatic steatosis is significantly associated with HBsAg seroclearance, which generally confers a favorable outcome in chronic HBV infection, 11 about 10% of patients with hepatic steatosis met current diagnostic criteria for nonalcoholic steatohepatitis and progressive fibrosis and cirrhosis develop in up to one-third of those with nonalcoholic steatohepatitis. 30 In conclusion, high body mass index associated with moderate-severe hepatic steatosis may contribute to HBsAg seroclearance in chronic HBV infection. These observations may be compatible with the findings of a recent populationbased study that HBsAg-positive subjects had less prevalence of metabolic syndrome than HBsAg-negative subjects. Further longitudinal studies are indicated to verify these observations.
